Back to Awarded Treatment Trials
Awarded Trial: 01T-057
Grant ID
01T-057
Illness
Schizophrenia
Primary Drug/Intervention
Rivastigmine
Primary Dosage
6mg b.i.d.
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Potkin
Sample Size
23
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
PANNS, CGI, ESRS, EEG, Cognitive battery
Results
Twenty-three patients completed the study. Patients receiving rivastigmine experienced a significant improvement in the Executive Function Domain of the cognitive battery. Rivastigmine treatment was also associated with improvement in neural synchrony, and normalized alpha power on EEG measures.
Publication
N/A
Link
N/A
PI Name
Steven Potkin
Degree
MD
Center
Department of Psychiatry and Human Behavior
Institution
University of California
Address
Irvine Hall, Room 161
City or Town
Irvine
State or Province
CA
Zip or Postal Code
92697
Country
USA
Email Address
sgpotkin@uci.edu